v3.26.1
Cover - USD ($)
12 Months Ended
Dec. 31, 2025
Mar. 20, 2026
Jun. 30, 2025
Cover [Abstract]      
Document Type 10-K/A    
Amendment Flag true    
Amendment Description Immix Biopharma, Inc. (the “Company”) is filing this Amendment No. 1 on Form 10-K/A (this “Amendment”) to amend its Annual Report on Form 10-K for the year ended December 31, 2025, previously filed with the Securities and Exchange Commission (the “SEC”) on March 25, 2026 (the “Original Filing”), for the sole purpose of reflecting the correct date of the Report of Independent Registered Public Accounting Firm (the “Auditor Report”) (correct: March 25, 2026). No other changes have been made to the financial reports or 10-K content compared to the 10-K filed on March 25, 2026.In addition, pursuant to the rules of the SEC, the exhibit list included herewith reflects currently-dated auditor consent and certifications from the Company’s Chief Executive Officer and Chief Financial Officer, which are filed as exhibits to this Amendment No. 1.Except for the foregoing amended information, this Amendment No. 1 does not amend or update any other information contained in the Original Filing, or reflect any events that have occurred after the filing of the Original Filing. Accordingly, this Amendment No. 1 should be read in conjunction with the Original Filing.    
Document Annual Report true    
Document Transition Report false    
Document Period End Date Dec. 31, 2025    
Document Fiscal Period Focus FY    
Document Fiscal Year Focus 2025    
Current Fiscal Year End Date --12-31    
Entity File Number 001-41159    
Entity Registrant Name IMMIX BIOPHARMA, INC.    
Entity Central Index Key 0001873835    
Entity Tax Identification Number 45-4869378    
Entity Incorporation, State or Country Code DE    
Entity Address, Address Line One 11400 West Olympic Blvd.    
Entity Address, Address Line Two Suite 200    
Entity Address, City or Town Los Angeles    
Entity Address, State or Province CA    
Entity Address, Postal Zip Code 90064    
City Area Code (310)    
Local Phone Number 651-8041    
Title of 12(b) Security Common stock, $0.0001 par value    
Trading Symbol IMMX    
Security Exchange Name NASDAQ    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company true    
Elected Not To Use the Extended Transition Period false    
Entity Shell Company false    
Entity Public Float     $ 35,708,995
Entity Common Stock, Shares Outstanding   52,964,549  
Documents Incorporated by Reference [Text Block] Portions of the registrant’s definitive proxy statement (the “2026 Proxy Statement”) relating to its 2026 annual meeting of stockholders (the “2026 Annual Meeting of Stockholders”) are incorporated by reference into Part III of this Annual Report on Form 10-K where indicated. The 2026 Proxy Statement will be filed with the U.S. Securities and Exchange Commission within 120 days after the end of the fiscal year to which this report relates.    
ICFR Auditor Attestation Flag false    
Document Financial Statement Error Correction [Flag] false    
Auditor Firm ID 173    
Auditor Name Crowe LLP    
Auditor Location Los Angeles, California